Premium
Xultophy: combination therapy for the treatment of type 2 diabetes
Author(s) -
Chaplin Steve,
Patel Vinod
Publication year - 2015
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1382
Subject(s) - medicine , type 2 diabetes , incretin , adverse effect , intensive care medicine , diabetes mellitus , combination therapy , endocrinology
Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.